Remus Pharmaceuticals Limited
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
What Remus files
- Others54
- Investor Meet16
- Important11
- Board Meeting11
- Updates9
- Dividend/Bonus8
Remus Board appointed an Independent Director. It approved migrating to the Main Board and forming a subsidiary in the Dominican Republic to expand its pharmaceutical business internationally. These strategic steps aim for growth and market presence.
Remus Pharma's board approved appointing Ashutosh Valani (ex-Beardo founder) as an Independent Director. They also plan to migrate to the NSE & BSE Main Boards and establish a new subsidiary in the Dominican Republic for global expansion.
Remus Pharma reported strong FY26 consolidated results: Revenue ₹853.63 Cr (+37.6% YoY), EBITDA ₹56.69 Cr (+24.1%), PAT ₹46.17 Cr (+20.2%). The company significantly expanded its market presence, launched new products including Semaglutide, and achieved robust growth in its high-margin B2C segment.
Remus Pharmaceuticals has opened its new branch office in Singapore. This strategic move aims to explore and capitalize on new business opportunities in the region.
Remus Pharma's H1-FY26 consolidated PAT rose 33.97% to INR 17.50 Cr, with revenue up 46.80% to INR 400.20 Cr. Operational highlights include tender wins in Nicaragua, 37 new product approvals, a new therapeutic segment launch, and market entry into Algeria.